Neumora Therapeutics (NMRA) Liabilities and Shareholders Equity (2022 - 2026)

Neumora Therapeutics' Liabilities and Shareholders Equity history runs 5 years deep, the most recent figure standing at $153.9 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 40.07% year-over-year to $153.9 million in Q1 2026; TTM through Mar 2026 was $746.6 million, a 43.9% decrease from a year earlier, with the FY2025 full-year figure at $191.0 million, down 39.73% from the prior year.
• Liabilities and Shareholders Equity retreated to $153.9 million in Q1 2026 per NMRA's latest filing, from $191.0 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $544.7 million in Q3 2023 and bottomed at $153.9 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $334.8 million (2024), against an average of $332.9 million.
• Across the five-year window, Liabilities and Shareholders Equity increased 16.41% in 2023 and slumped 49.56% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $426.2 million in 2022, then grew by 16.41% to $496.2 million in 2023, then plunged by 36.12% to $317.0 million in 2024, then plunged by 39.73% to $191.0 million in 2025, then slipped by 19.46% to $153.9 million in 2026.
• Per Business Quant, the three latest NMRA Liabilities and Shareholders Equity figures stand at $153.9 million (Q1 2026), $191.0 million (Q4 2025), and $177.8 million (Q3 2025).